Integrated Treatment of Sickle Cell Disease Patient with Associated Thyroid Complications

According to several studies, the prevalence of hypothyroidism in SCA patients ranges from 2 to 6%. In India, there is no regular practice for screening for hypothyroidism, despite the negative effects it can have on people with sickle cell anemia. In this case report, we present a case exhibiting the impact of integrated therapy on the clinical response of a 35-year-old woman suffering from sickle cell disease and thyroid disorder. She is suffering from sickle cell disease but considering her complications she was prescribed hydroxyurea for critical complications 11 years prior. After adhering to treatment for more than 6 years she started complaining of weight fluctuation, mood swings and palpitation and experienced sickling-induced complications. She was diagnosed with a thyroid disorder in 2019. She was started on thyroxine and hydroxyurea but her complications and issues did not resolve. Considering her unresolved problem she developed hypothyroidism-associated complications and visited the clinic. With prior knowledge and consent, the 300 mg T-AYU-HM Premium integrated treatment was initiated along with thyroxine. The Hydroxyurea treatment was discontinued. Throughout the treatment, the patient’s general health continued to improve. The TSH which was once 150 on the day of the visit increased to 38.87. The RBC was also improvised from 3.83 million/mm3 to 4.29 million/mm3. Over two years, the patient showed significant improvements in her symptoms and balancing of thyroid function. This strategy was safer, less expensive and has therapeutic potential for treating sickle cell anemia with thyroid disorder. No adverse reactions were noted.